Y-Mabs Therapeutics Inc [YMAB] Insider Selling: Time to sell?

Y-Mabs Therapeutics Inc’s recently made public that its CHIEF BUSINESS OFFICER Gad Thomas unloaded Company’s shares for reported $64116.0 on Mar 05 ’24. In the deal valued at $16.44 per share,3,900 shares were sold. As a result of this transaction, Gad Thomas now holds 158,700 shares worth roughly $2.57 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Rajah Vignesh sold 1,711 shares, generating $28,283 in total proceeds. Upon selling the shares at $16.53, the SVP & CHIEF MEDICAL OFFICER now owns 33,889 shares.

Before that, Smith Susan Laura sold 1,682 shares. Y-Mabs Therapeutics Inc shares valued at $27,837 were divested by the SVP & CHIEF COMMERCIAL OFFICER at a price of $16.55 per share. As a result of the transaction, Smith Susan Laura now holds 33,918 shares, worth roughly $0.55 million.

Wedbush upgraded its Y-Mabs Therapeutics Inc [YMAB] rating to an Outperform from a a Neutral in a research note published on May 10, 2023; the price target was increased to $13 from $5. A number of analysts have revised their coverage, including Guggenheim’s analysts, who decreased its forecast for the stock in early April from “a Buy” to “a Neutral”. Morgan Stanley also remained covering YMAB and has decreased its forecast on January 27, 2023 with a “an Underweight” recommendation from previously “an Equal-weight” rating. Cowen revised its rating on January 05, 2023. It rated YMAB as “a Market perform” which previously was an “an Outperform”.

Price Performance Review of YMAB

On Monday, Y-Mabs Therapeutics Inc [NASDAQ:YMAB] saw its stock fall -0.43% to $16.19. Over the last five days, the stock has lost -0.25%. Y-Mabs Therapeutics Inc shares have risen nearly 137.39% since the year began. Nevertheless, the stocks have risen 399.69% over the past one year. While a 52-week high of $20.90 was reached on 03/01/24, a 52-week low of $3.13 was recorded on 01/03/24. SMA at 50 days reached $14.85, while 200 days put it at $8.28. A total of 0.65 million shares were traded, compared to the trading of 0.27 million shares in the previous session.

Levels Of Support And Resistance For YMAB Stock

The 24-hour chart illustrates a support level at 15.48, which if violated will result in even more drops to 14.78. On the upside, there is a resistance level at 17.19. A further resistance level may holdings at 18.20. The Relative Strength Index (RSI) on the 14-day chart is 53.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.65, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 33.94%. Stochastics %K at 68.49% indicates the stock is a holding.

How much short interest is there in Y-Mabs Therapeutics Inc?

A steep rise in short interest was recorded in Y-Mabs Therapeutics Inc stocks on Mar 15, 2024, dropping by 100000.0 shares to a total of 2.1 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 2.2 million shares. There was a decline of -4.76%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 5.76% of the overall stock float, the days-to-cover ratio (short ratio) fell to 5.78.

Most Popular